- Previous Close
9.37 - Open
9.47 - Bid 6.91 x 200
- Ask 11.49 x 200
- Day's Range
8.91 - 9.68 - 52 Week Range
2.91 - 12.40 - Volume
1,206,048 - Avg. Volume
1,922,507 - Market Cap (intraday)
557.873M - Beta (5Y Monthly) 1.42
- PE Ratio (TTM)
-- - EPS (TTM)
-2.22 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.17
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
www.monterosatx.comRecent News: GLUE
View More
Performance Overview: GLUE
Trailing total returns as of 10/30/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLUE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLUE
View MoreValuation Measures
Market Cap
575.06M
Enterprise Value
357.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
96.89
Price/Book (mrq)
2.56
Enterprise Value/Revenue
62.03
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.99%
Return on Equity (ttm)
-59.51%
Revenue (ttm)
5.76M
Net Income Avi to Common (ttm)
-130.41M
Diluted EPS (ttm)
-2.22
Balance Sheet and Cash Flow
Total Cash (mrq)
262.2M
Total Debt/Equity (mrq)
19.74%
Levered Free Cash Flow (ttm)
-57.04M
Research Analysis: GLUE
View MoreCompany Insights: GLUE
GLUE does not have Company Insights